Altimmune's stock sinks on mixed phase 2 MASH results for GLP-1 drug
Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 metabolic dysfunction-associated steatohepatitis study, while still showcasing the asset’s weight loss potential.
Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 metabolic dysfunction-associated steatohepatitis study, while still showcasing the asset’s weight loss potential.
